Skip to Content
Søg Menu

Highlights fra ASCO GU 2024 om blærekræft i en dansk kontekst

Dag Stormoen, læge og ph.d.-studerende, Afdeling for Kræftbehandling, Rigshospitalet, præsenterer i denne MEDtalk, hvilke nye data om blærecancer, han tager med hjem fra ASCO GU 2024.
Dag Rune Stormoen

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Marc Eid og Karl Semaan

Cancer Epigenomics Improve the Overall Survival and the Quality of Life

/ Marc Eid / Karl Semaan
ASCOGU24Prostatacancer Play the Video 1:31
Wadih Issa

Comparing Downstaging in RCC-Patients with Tumor or Without Tumor Thrombus Receiving Neoadjuvant ICI Regimen

/ Wadih Issa
ASCOGU24Nyrecancer Play the Video 1:47
Eddy Saad

Understanding Mechanisms Behind Acquired Resistance to Immunotherapy in Metastatic Renal Cell Carcinoma

/ Eddy Saad
ASCOGU24Nyrecancer Play the Video 2:21
Renee Maria Saliby

The Potential for Intermediate Clinical Endpoints as Surrogates for Overall Survival

/ Renee Maria Saliby
ASCOGU24Nyrecancer Play the Video 2:46
Jakob Lauritsen

Highlights fra ASCO GU 2024 om prostatacancer i en dansk kontekst

/ Jakob Lauritsen
ASCOGU24Prostatacancer Play the Video 4:21
Philipp Ivanyi

Real-World Evidence on Lenvatinib plus Everolimus in Patients with Pre-Treated Advanced Renal Cell Carcinoma

/ Philipp Ivanyi
ASCOGU24Nyrecancer Play the Video 3:16
Ahmed Rehan

Real-World Data on Maintenance Avelumab Treatment

/ Ahmed Rehan
ASCOGU24Blærecancer Play the Video 2:14

ASCO GU 2024: CheckMate 914 Trial – Adjuvant Nivolumab Monotherapy vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy

/ Sofie Pohl
ASCOGU24Nyrecancer
Petros Grivas

Long-Term Patient-Reported Outcomes Data from the JAVELIN Bladder 100 Trial in Patients with Advanced Urothelial Carcinoma

/ Petros Grivas
ASCOGU24Blærecancer Play the Video 02:14
Back to top